Alterations in expression and in serum activity of dipeptidyl peptidase IV (DPPIV, CD26) in patients with hyporectic eating disorders

Scandinavian Journal of Immunology

Volumn 50, Issue 5, 1999, Pages 536-541

  Hildebrandt, M ^a   Rose, M ^a   Mayr, C ^a   Schuler C ^b   Reutter, W ^c   Salama, A ^a   Klapp, B F ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV;

ADULT; ANOREXIA NERVOSA; ARTICLE; BULIMIA; CLINICAL ARTICLE; CONTROLLED STUDY; EATING DISORDER; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNE RESPONSE; MALNUTRITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

EID: 0032741608     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1999.00612.x     Document Type: Article

References (32)

1. Pomeroy C, Mitchell JE, Eckert E. Risk of infection and immune function in anorexia nervosa. Int J Eat Disord 1992;12:47-55.
2. Marcos A, Varela P, Santacruz I, Munoz-Velez A, Morande G. Nutritional status and immunocompetence in eating disorders. Eur J Clin Nutr 1993;47:787-93.
3. Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP. Effect of body weight and caloric restriction on serum complement proteins, including factor D/adipsin: Studies in anorexia nervosa and obesity. Clin Exp Immunol 1997;108:507-515.
4. Wyatt RJ, Farrell M, Berry PL, Forristal J, Maloney MJ, West CD. Reduced alternative complement pathway control protein levels in anorexia nervosa: Response to parenteral alimentation. Am J Clin Nutr 1982;35:973-80.
5. Barbouche MR, Levy-Soussan P, Corcos M, et al. Anorexia and lower vulnerability to infections. Am J Psychiat 1993;150:169-70.
6. Rieger W, Brady JP, Weisberg E. Hematologic changes in anorexia nervosa. Am J Psychol 1978:135:984-5.
7. Allende LM, Corell A, Manzanares J, et al. Immunodeficiency associated with anorexia nervosa is secondary and improves after refeeding. Immunology 1998;94:543-51.
8. Fink S, Eckert E, Mitchell J, Crosby R, Pomeroy C. T lymphocyte subsets in patients with abnormal body weight: Longitudinal studies in anorexia nervosa and obesity. Int J Eat Disord 1996;20:295-305.
9. Cason J, Ainley C, Wolstencroft RA, Norton KRW, Thompson RPH. Cell-mediated immunity in anorexia nervosa. Clin Exp Immunol 1986;64:370-5.
10. Reutter W, Baum O, Löster K, et al. Functional aspects of the three extracellular domains of dipeptidyl peptidase IV. Characterization of glycosylation events, of the collagen-binding site and of endopeptidase activity. In: Fleischer B, ed. Dipeptidyl Peptidase IV (CD26) in Metabolism and Immune Response. Heidelberg: Springer-Verlag, 1995:55-73.
11. Tanaka T, Duke-Cohan JS, Kameoka J, et al. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA 1994;91:3082-6.
12. Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997;186:1865-72.
13. Proost P, Struyf S, Schols D, et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1 alpha. FEBS Lett 1998;432:73-76.
14. Bauvois B, Sanceau J, Wietzerbin J. Human U937 cell surface peptidase activities: Characterization and degradative effect on tumor necrosis factor- alpha. Eur J Immunol 1992;22:923-930.
15. Blanco J, Marie I, Callebaut C, Jacotot E, Krust B, Hovanessian AG. Specific binding of adenosine deaminase but not HIV-1 transactivator protein Tat to human CD26. Exp Cell Res 1996;225:102-11.
16. De Meester IA, Kestens LL, Vanham GL, et al. Costimulation of CD4(+) and CD8(+) T cells through CD26: The ADA-binding epitope is not essential for complete signaling. J Leuk Biol 1995;58:325-30.
17. Kreisel W, Heussner R, Volk B, Büchsel R, Reutter W, Gerok W. Identification of the 110000 Mr glycoprotein isolated from rat liver membrane as dipeptidylaminopeptidase IV. FEBS Lett 1982; 147:85-8.
18. Scharpé S, De Meester I, Vanhoof G, et al. Serum dipeptidyl peptidase IV activity in transplant recipients. Clin Chem 1990; 36:984.
19. Korom S, De Meester I, Stadlbauer T, et al. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 1997;63:1495-500.
20. Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J Immunol 1996;156:1714-21.
21. Dally P. Anorexia Nervosa London: William Heinemann Medical Books, 1969.
22. Uematsu T, Urade M, Yamaoka M. Decreased expression and release of dipeptidyl peptidase IV (CD26) in cultured peripheral blood T lymphocytes of oral cancer patients. J Oral Pathol Med 1998;27:106-10.
23. Maes M, De Meester I, Scharpe S, Desnyder R, Ranjan R, Meltzer HY. Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: Effects of antidepressants and antipsychotic drugs. Acta Psychiatr Scand 1993;93:1-8.
24. Stefanovic V, Ardaillou N, Vlahovic P, Placier S, Ronco P, Ardaillou R. Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology 1993;80:465-70.
25. Carmichael KA, Carmichael DH. Bone metabolism and osteopenia in eating disorders. Medicine (Baltimore) 1995;74:254-67.
26. Maes M, Meltzer HY, Scharpe S, et al. Relationships between lower plasma L-tryptophan levels and immune- inflammatory variables in depression. Psychiat Res 1993;49:151-65.
27. Kameoka J, Sato T, Torimoto Y, et al. Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood 1995;85:1132-7.
28. Vanham G, Kestens L, De Meester I, et al. Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J Acquir Immune Defic Syndr 1993; 6:749-57.
29. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994;84:3261-82.
30. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585-96.
31. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998;47:764-9.
32. Drucker DJ, Shi Q, Crivici A, et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nature Biotechnol 1997;15:673-7.